Agusti Al., M. Decramer, R. Baltolome et al. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2017 , Available from: http://goldcopd.org/
Hubbard R. The burden of lung disease. Thorax. 2006; 61 (7): 557–558
Buist AS, MA McBurnie, WM Vollmer et al. for BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007; 370 (9589): 741–750.
Buist AS, W Vollmer, S Sullivan, et al. The burden of obstructive lung disease Initiative (BOLD): rationale and design. COPD 2005; 2 (2): 277-283.
Trupin L, G Earnest, M San Pedro, et al. The occupational burden of chronic obstructive pul monary disease. Eur Respir J. 2003; 22 (3): 462-469
Hill Suzanne R., L. Olson, Y. Falck-Ytter, A. Cruz, D. Atkins, M. Baumann, R. Jaeschke, T. Woitalla, H. Schunemann; on behalf of the ATS/ERS AdHoc Committee on Integrating and Coordinating Efforts in COPD Guideline Developmen. Incorporating Considerations of Cost-Effectiveness, Affordability, and Resource Implications in Guideline Development. Proc Am Thorac Soc 2012; 9, (5): 251-255
http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/
http://www.staywellhealthmanagement.com/ LinkClick.aspx?fileticket=Ir-GCYQoTOpo%3D&t
Ramsey S., S. Sullivan. The burden of illness and economic evaluation for COPD. Resp Med., Europ Respir J 2003; 21: 29s–35
DW, G. McMillan, F. Frost et al. Predicting the cost of managing patients with chronic obstructive pulmonary disease. Resp Med 2005; 99: 1325-33
Mapel Douglas W., M. Schum, E. Lydick, J. Marton. A New Method for Examining the Cost Savings of Reducing COPD Exacerbations. Pharmacoeconomics 2010; 28 (9): 733-749
Najafzadeh M, C A Marra, M Sadatsafavi, S D Aaron, S D Sullivan, K L Vandemheen, P W Jones, J M Fitzgerald. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax 2008; 63: 962–967.
daCosta DiBonaventura M., R. Paulose-Ram, J. Su, M. McDonald, K. H. Zou, J-S. Wagner. The Impact of COPD on Quality of Life, Productivity Loss, and Resource Use among the Elderly US Workforce. COPD: J of Chronic Obstructive Pulmonary Dis,2012; 9 (1): 46-57
Herse F., T. Kiljander, L. Lehtimäki. Annual costs of chronic obstructive pulmonary disease in Finland during 1996–2006 and a prediction model for 2007–2030. Primary Care Respiratory Medicine (2015) 25, 15015;
Jakobsen M, Anker N, Dollerup J, Poulsen PB and Lange P. Study on drug costs associated with COPD prescription medicine in Denmark. Clin Respir J 2013; 7: 328–337.
Tsiligianni I.G. COPD patients trapped in the fi nancial crisis in rural Crete. The Lancet 2013; 1: e31-e32
Simoens S. Cost-effectiveness of pharmacotherapy for COPD in ambulatory care: a review. J of Evaluation of Clinical Practice 2013; 19: 1004–1011
Stuart, B. C., Simoni-Wastila, L., Zuckerman, I. H., Davidoff, A., Shaffer, T., Yang, H. W., Qian, J., Dalal, A.A., Mapel, D. W., BryantComstock, L. Impact of maintenance therapy on hospitalization and expenditures for Medicare beneficiaries with chronic obstructive pulmonary disease. The American Journal of Geriatric Pharmacotheraphy, 2010; 8 (5): 441–453
D’Souza,A.O.,Smith,M.J.,Miller,L.A.&Kavookjian,J. An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD. Chest, 2006; 129 (6):1693–1708.
Hogan, T. J., Geddes, R. & Gonzalez, E. R. An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease. Clinical Therapeutics, 2003; 25 (1), 285– 297
Starkie H., Briggs A. H. & Chambers, M. G. Pharmacoeconomics in
COPD: lessons for the future. International Journal of Chronic Obstructive Pulmonary Disease, 2008; 3 (1): 71–88.
Nowak, D., Berger, K., Lippert, B., Kilgert, K., Caeser, M. & Sandtmann, R. Epidemiology and health economics of COPD across Europe: a critical analysis. Treatments in Respiratory Medicine,2005; 4 (6), 381–395.
Jones P., Wilson K., Sondhi S., Cost-effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: an economic evaluation. Respiratory Med, 2003; 97(1): 20-26
Earnshaw, S. R., Wilson, M. R., Dalal, A. A., Chambers, M. G., Jhingran, P., Stanford, R., Mapel, D. W. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD. Respiratory Medicine, 2009; 103 (1): 12–21.
Price, D., Gray, A., Gale, R., Asukai, Y., Mungapen, L., Lloyd, A., Peters, L., Neidhardt, K., Gantner, T. Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD. Respiratory Medicine, 2011; 105 (11):1635–1647.
Akazawa M., Biddle A., Stearns S., Economic assessment of early initiation of inhaled corticosteroids in chronic obstructive pulmonary disease using propensity score matching. Clinical Therapeutics, 2008; 30: 1003-16.
Akazawa, M., Stearns, S. C. & Biddle, A. K. Assessing treatment effects of inhaled corticosteroids on medical expenses and exacerbations among COPD patients: longitudinal analysis of managed care claims. Health Services Research, 2008; 43 (6): 2164–2182
Rutten-van Molken M., Van Doorslaer E., Jansen M., Kerstjens H., Rutten F., Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease. American J of Respiratory and Critical Care Med, 1995; 151(4): 975-982
Akazawa M., Halpern R., Riedel A., Stanford R., Dalal A., Blanchette C. Economic burden prior to COPD diagnosis: a matched case-control study in the United States. Respiratory Medicine, 2008; 102 (12): 1744–1752.
Maureen P., Rutten-van Molken, Jan B., Oostenbrink E., M. Miravitlles, B. Monz, Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ 2007; 8:123-135
van der Palen, J., Monninkhof, E., van der Valk, P., Sullivan, S. D. & Veenstra, D. L. Cost effectiveness of inhaled steroid withdrawal in outpatients with chronic obstructive pulmonary disease Thorax, 2006; 61: 29–33
de Miguel-Diez J., Carrasco-Garrido P., Rejas-Gutierrez J., MartinCenteno A., Gobartt-Vazquez E., Hernandez-Barrera V., Gil de M., Jimenez-Garcia R., Inappropriate overuse of inhaled corticosteroids for COPD patients: impact on health costs and health status. Lung, 2011; 189 (3): 199-206.
Minkoff, N. B. Analysis of the current care model of the COPD patient: a health outcomes assessment and economic evaluation. Journal of Managed Care Pharmacy, 2005; 6 :S3–S7.
Friedman, M., Serby, C. W., Menjoge, S. S., Wilson, J. D., Hilleman, D. E. & Witek, T. J., Jr Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest, 1999; 115 (3): 635–641.
Ruchlin, H. S. & Dasbach, E. J. An economic overview of chronic obstructive pulmonary disease. Pharmacoeconomics, 2001; 19 (6): 623–642.
Akazawa M., Halpern R., Riedel A., Stanford R., Dalal A., Blanchette C., Economic burden prior to COPD diagnosis: a matched case-control study in the United States. Respiratory Medicine, 2008; 102 (12):1744-52.
Mauskopf J., Baker C., Monz B., Juniper M., Cost effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidence. Journal of Medical Economics, 2010; 13 (3):403–417.
Zaniolo, O., Iannazzo, S., Pradelli, L. & Miravitlles, M. Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy. The European Journal of Health Economics, 2012; 13: 71–80.
Hoogendoorn M., Al M., Beeh K., Bowles D., von der Schulenburg J., Lungershausen J., Monz B., Schmidt H., Vogelmeier, C., Rutten-van Molken, M. P. Cost-effectiveness of tiotropium versus salmeterol: the POETCOPD trial. The European Respiratory Journal, 2013; 41 (3):556–564.
Gani, R., Griffin, J., Kelly, S. & Rutten-van, M. M. Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD. Primary Care Respiratory Journal, 2010; 19 (1): 68–74.
Lee K., Phua J., Lim T., Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore. Respiratory Med, 2006; 100 (12): 2190-96
Neyt M., Van den Bruel A., Gailly J., Thiry N., Devriese S., Tiotropium in the treatment of chronic obstructive pulmonary disease: Health Technology Assess. Brussels: Belgian Health Care Knowledge Centre. 2009
Naik, S., Kamal, K. M., Keys, P.A. & Mattei, T. J. Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease (Structured abstract). ClinicoEconomics and Outcomes Research, 2010; 2: 25–36.
Rice, K. L., Kunisaki, K. M. & Niewoehner, D. E. Role of tiotropium in the treatment of COPD. International Journal of Chronic Obstructive Pulmonary Disease, 2007; 2 (2: 95–105
Neyt, M., Devriese, S., Thiry, N. & Van den Bruel, A. Tiotropium’s costeffectiveness for the treatment of COPD: a cost-utility analysis under realworld conditions. BMC Pulmonary Medicine, 2010;10: 47.
Moretti, M., Bottrighi, P., Dallari, R., Da Porto, R., Dolcetti, A., Grandi, P., Garuti, G., Guffanti, E., Roversi, P., De Gugliemo, M., Potena,A. The effect of long-term treatment wither dosteine on chronic obstructive pulmonary disease: the EQUALIFE Study. Drugs Under Experimental and Clinical Research, 2004; 30 (4): 143–152.
Montuschi P, Kharitonov S.A,Ciabattoni G, Barnes P.J. Exhaled leukotrienes and prostaglandins in COPD. Thorax 2003;58:585-588
Prescott W et al. Randomized Trial of Zileuton for Treatment of COPD Exacerbations Requiring Hospitalization. Journal of Chronic Obstructive Pulmonary disease:2011; 8(1);21-29
Gompertz S., Stockley A., A randomized, placebo-controlled trial of leukotriene synthesis inhibitor in patients with COPD. Chest 2002; 122(1):289-294.
Jubran A., Gross N., Ramsdell J., Simonian R., Schuttenhelm K., Sax M., Kaniecki D., Arnold R., Sonnenberg F., Comparative cost-effectiveness analysis of theophylline and ipratropium bromide in chronic obstructive pulmonary disease. A threecenter study. Chest, 1993; 103 (3): 678–684.
Starkie H., Briggs A., Chambers M., Pharmacoeconomics in COPD: lessons for the future. International Journal of Chronic Obstructive Pulmonary Disease, 2008; 3 (1): 71–88.
Rutten-van Molken M., van Nooten F., Lindemann, M., Caeser, M. & Calverley, P. M. A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease. Pharmacoeconomics, 2007; 25(8): 695–711
Sun S., Marynchenko M., Banerjee R. et al., Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD. J Med Economics, 2011; 14 (6): 805-815
Hertel N., Kotchie R., Samyshkin Y., Radford M., Humphreys S., Jameson K., Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis. Inter J of Chronic Obstructive Pulmonary Dis, 2012; 7: 183-199
Neyt, M., Devriese, S., Thiry, N. & Van den Bruel, A. Tiotropium’s costeffectiveness for the treatment of COPD: a cost-utility analysis under realworld conditions. BMC Pulmonary Medicine, 2010; 10: 47.
Gagnon, Y. M., Levy, A. R., Spencer, M. D., Hurley, J. S., Frost, F. J., Mapel, D. W., Briggs, A. H. Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organization. Respiratory Medicine, 2005; 99 (12): 1534–1545
Chuck A., Jacobs P., Mayers I., Marciniuk D., Cost effectiveness of combination therapy for chronic obstructive pulmonary disease. Canadian Respiratory Jour: J of the Canadian Thoracic Society, 2008; 15 (8): 437-443
Fritscher, L. & Chapman, K. R. Seretide: a pharmacoeconomic analysis. J. Medical Economics, 2008; 11 (3): 555–570.
Briggs, A. H., Glick, H. A., Lozano-Ortega, G., Spencer, M., Calverley, P. M., Jones, P. W., Vestbo, J. Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. The European Respiratory Journal, 2010;35 (3): 532– 539
Oba Y., Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD. The Am J of Managed Care, 2009; 15 (4): 226–232.
Dalal, A. A., Roberts, M. H., Petersen, H. V., Blanchette, C. M. & Mapel, D. W. Comparative cost-effectiveness of a fluticasonepropionate/salmeterol
combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease, 2011; 6: 13-22.
Delea,T.E.,Hagiwara,M.,Dalal,A.A.,Stanford,R.H.&Blanchette, C. M. Healthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol vs other inhaled maintenance therapies. Current Medical Research and Opinion, 2009; 25 (1): 1-13.
Rascati, K. L., Akazawa, M., Johnsrud, M., Stanford, R. H. & Blanchette, C. M. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen. Clinical Therapeutics, 2007; 29 (6): 1203-1213.
Ruben D Restrepo Melissa T Alvarez Leonard D Wittnebel et al. Medication adherence issues in patients treated for COPD. International Journal of COPD 2008:3(3) 371-384
van Boven JF, Chavannes NH, van der Molen T, Rutten-van Mölken MP, Postma MJ, Vegter S. Clinical and economic impact of non-adherence in COPD: a systematic review. Respir Med. 2014; 108 (1): 103-13
Dal Negro, R., Eandi, M., Pradelli, L. & Iannazzo, S. Costeffectiveness and healthcare budget impact in Italy of inhaled corticosteroids and brochodilators for severe and very severe COPD patients (Structured abstract). International Journal of Chronic Obstructive Pulmonary Disease, 2007; 2 (2): 169-176.
Dalal, A.A., St, C. M., Petersen, H. V., Roberts, M. H., Blanchette, C. M. & Manavi-Zieverink, KCost-effectiveness of combination fluticasone propionate-salmeterol 250/50 microg versus salmeterol in severe COPD patients. International Journal of Chronic Obstructive Pulmonary Disease, 2010; 5: 179-187.
Akazawa, M., Halpern, R., Riedel, A.A., Stanford, R. H., Dalal, A. &
Blanchette, C. M. (2008) Economic burden prior to COPD diagnosis: a
matched case-control study in the United States. Respiratory Medicine, 2008; 102 (12):1744-1752.
Mittmann,N.,Hernandez,P.,Mellstrom,C.,Brannman,L.&Welte,T. Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease:Australian, Canadian and Swedish healthcare perspectives. Pharmacoeconomics, 2011; 29 (5): 403- 414
Halpin, D. M. (2008) Symbicort: a pharmacoeconomic review. Journal of Medical Economics, 11 (2), 345-36
Jakovljevic M, Djordjevic N, Jurisevic M, Jankovic S. Evolution of Serbian pharmaceutical market alongside socioeconomic transition. Expert Rev Pharmacoecon Outcomes Res (2015). doi:10.1586/
2015.1003044
Jakovljevic M, Nakazono S, Ogura S. Contemporary generic market in Japan - key conditions to successful evolution. Expert Rev Pharmacoecon Outcomes Res (2014) 14(2):181-94.
Medicines and Medical Devices Agency of Serbia. Available from:
http://www.alims.gov.rs/ciril/ o-agenciji/publikacije/ppl2012/
Cupurdija V. Cost Drivers of Community Acquired Pneumonia Treatment. University of Kragujevac: Serbia (2014). Doctoral Dissertation.
Spyratos D., D. Chloros, D. Michalopoulou, L. Sichletidis. Estimating the extent and economic impact of under and overdiagnosis of chronic obstructive pulmonary disease in primary care. Chronic Respiratory Disease 2016; 13 (3): 240-246
Kostikas K., D. Bouros. `Show me the money": a fair criticism of economic studies on inhaled bronchodilators for COPD. BMC Pulmonary Medicine 2010, 10: 48
Diamantea F., K. Kostikas, K. Bartziokas, F. Karakontaki, S. Tsikrika et al. Prediction of Hospitalization Stay in COPD Exacerbations: The AECOPD-F Score. Respir Care 2014; 59(11): 1679-1686.
Alexopoulos E., Foteini M., E. Mitsiki, E. Bania, C. Varounis, K. Gourgoulianis. Frequency and risk factors of COPD exacerbations and hospitalizations: a nationwide study in Greece (Greek Obstructive Lung Disease Epidemiology and health ecoNomics: GOLDEN study. International Journal of COPD 2015: 10 : 2665-2674
Geitona M, Hatzikou M, Steiropoulos P, Alexopoulos EC, Bouros D. The cost of COPD exacerbations: a university hospital-based study in Greece. Respir Med. 2011 105(3): 402-9.
Dahl, R., et.al., Efficacy and safety of AVA149 compared to the concurrent administration of its monocomponencts indacaterol and glycopyrronium: the BEACON study. International Journal of COPD 2012; 501-508
Wedzicha J., et.al., Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study, The Lancet Respiratory Medicine, 2013; 1 (3) :199 - 209
Katsenos S., S. Constantopoulos. Long-term oxygen therapy in COPD: factors affecting and ways of improving patient compliance. Pulmonary Medicine 2011; 8 doi:10.1155/2011/325362
Mäkelä MJ1, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med. 2013;107(10):1481-90
Kyriopoulos I-J., D. Zavras, A. Skroumpelos. et al. Barriers in access to health care services for chronic patients in time of austerity: an empirical approach in Greece. International Journal for Equity in Health 2014, 13:54 http://www.equityhealthj.com/content/13/1/54
Bitsaki M., C. Coutras, G. Coutras et al. Chronic online: Implementing mHealth solution for monitoring and early alerting in chronic obstructive pulmonary disease. Health information journal. 2016 21. pii:1460458216641480
Yanev N., N. Kyuchukov, Nikolova P., et al. COPD comorbidities - Do they add more cost? A 1-year follow-up study. European Respiratory Society Annual Congress, 2012
Andreevska K., Z. Dimitrova, R. Kofinov, V. Petkova. Evaluation of COPD treatment patterns for pulmonologists in Bulgaria. Trakia Journal of Sciences, 2010; 8 (2): 358-364
Kyuchukov N., P. Pavlov, P. Glogovska, T. Popova, N. Yanev, I. Krachunov, Z. Ivanova, Y. Ivanov, P. Hristova. Hospital treatment costs of exacerbations in COPD patients with indications for LTOT. European Respiratory Journal, 2016; 46: PA 1053
Андреевска К, Петкова В, Димитрова З. Медико-социален анализ на разпространението на хроничната обструктивна белодробна болест. Scripta Periodica, 2010; 2: http://www.medun.acad.bg/cmb_htm/
Scripta%20periodica/2-2010-original.html
Андреевска КГ, Mедико-социални и икономически проучвания на лекарствената употреба при пациенти с хронична обструктивна белодробна болест (хобб). авт. на дис. за получаване на научно-образователната степен “доктор”на Маг.фарм, София, 2010г.
Кючуков Н, Кръстева Н. и кол. Скрининг за ХОББ сред населението на Плевен. Торакална медицина, 2011; 3; 37-41.
Павлов П, Иванов Я, Глоговска П и кол. Нови епидемиологични данни за ХОББ в Плевенски регион. Торакална медицина, 2012; 2; 44-50.
Павлов П, Иванов Я и кол. Болестност от ХОББ сред пушачи – епидемиологично проучване. Торакална медицина, 2011; 2; 50-53.
Ходжев В Екзацербации на ХОББ, http://brsnet.bg/wpcontent/uploads/2013/04/Pravetz2013_COPDexacerbations_dochodjev.pdf
Павлов П, Иванов Я и кол. Среден годишен спад на ФЕО1 при пациенти с тежка и много тежка ХОББ, лекувани с инхалаторни кортикостероиди. Торакална медицина, 2009; 2: 29-32.
Ivanov Y, Torossian A COPD morbidity screening in high risk groups. ERJ 2013; 42 (57): P4234, http://erj.ersjournals.com/content/42/Suppl_57/P4234.short
Angelova S et al economic evaluation of smoking induced lung diseases treatment and their social impact. International Journal of Development Research 2015; 5 (03): 3805-3810
Андреевска К, Петкова В и Димитрова З. маркетингов анализ на фармацевтичния пазар на хронична обструктивна белодробна болест (хобб) и астма за периода 2006-2009 Г. Scripta Periodica, 2010; 3
Глоговска П, Иванов Я, Христова П и кол., Фармакоикономическа оценка на стойността на лечение на амбулаторни и хоспитализирани пациенти с инфекции на дихателните пътища, придобити в обществото. Торакална медицина, 2010; 3: 52-56
Andreevska K, Petkova V, Dimitrova Zl Analysis of the COPD pharmaceutical market. Archives of the Balkan Med Union, 2011; 46 (1): 73-76.
Yanev N High risk COPD patients cost less if treated according to GOLD 2011 recommendations, ERJ, 2013; 42 (57): P1536,
Andreevska K, Dimitrova Zl, Kofinov R, Petkova v evaluation of copd treatment patterns for pulmonologists in bulgaria. trakia Journal of Sciences, 2010; 8 (2): 358-364.
Grekova D Marketing analysis of asthma and copd products on the pharmaceutical market in bulgaria for 2011, 2012 FIP Congress in Amsterdam (the Netherlands), http://www.fip.org/?page=abstracts&action=generatePdf&item=7948.
Yanev N et al COPD comorbidities - Do they add more cost? A 1-year follow-up study, ERJ, 2012; 40 (56): P1002, http://erj.ersjournals.com/content/40/ Suppl_56/P1002.short.
Димитрова А. Промени в качеството на живот след приложена кинезитерапия при болни с хронична обструктивна белодробна болест. InSpiro 2011; 2 (14).
Andreevska K, Petkova V et al effect of education on patients with chronic obstructive pulmonary disease, world journal of pharmacy and pharmaceutical sciences. 2014; 3 (3)
Камушева M., Петрова Д., Георгиев О., Димитрова М., Петкова В., Петрова Г., Разходи за лечение и качество на живот на пациентите с ХОББ в България – систематичен литературен преглед, Торакална медицина, 7 (2), 2015, 26-42
Andreevska К., V Petkova, S Jordanova, D Grekova, V Madjarov, M. Dimitrova, G.Petrova, S. Guerguiev, M. Dimitrov. Effect of education on patients with chronic obstructive pulmonary disease , WJPPS 2014, 3 (3), 01-09
Павлов П., Я. Иванов, П. Глоговска и кол., Нови епидемиологични данни за ХОББ в Плевенски регион, Торакална медицина, 2012, 2 (ІV); 44-50.
Павлов П., Я. Иванов и кол., Болестност от ХОББ сред пушачи – епидемиологично проучване, Торакална медицина, 2011, 2 (ІІ); 50-53;
Krachunov I .et al., Air pollution, outdoor temperatures, and their impact on acute exacerbations of COPD, ERJ 2014 1 (44), Suppl 58 : 4123. http://erj.ersjournals.com/content/44/Suppl_ 58/P4123.short
Кючуков Н., Н. Кръстева и кол., Скрининг за ХОББ сред населението на Плевен, Торакална медицина, 2011, бр. 3 (ІІ); 37-41.
Павлов П., Я. Иванов, П. Глоговска и кол., Нови епидемиологични данни за ХОББ в Плевенски регион, Торакална медицина, 2012, 2 (ІV); 44-50.
Андреевска К., В. Петкова, Зл. Димитрова: Медико-социален анализ на разпространението на ХООБ, Scripta periodica, 2010, 2 (13),, 9-20;
Kamusheva M., M. Dimitrova, Jov van Boven, et al. Clinical characteristics, treatment patterns, and socio-economic burden of COPD in Bulgaria. Journal of medical economics 2017; 20 (5): 503-509
